Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 31.03.2026 CHPS.LN IE000KXTLDE2 700,002.00 USD 23,303,132.65 33.290  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 31.03.2026 MISL.LN IE000NVDQXE1 3,775,002.00 USD 126,273,499.21 33.450  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 31.03.2026 QSEP.LN IE000FQ808R5 450,002.00 USD 10,038,400.67 22.307  ...
-

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending

STOCKHOLM, Sweden--(BUSINESS WIRE)--Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a g...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 31.03.2026 GMAY.LN IE000P0FL8E3 900,002.00 USD 34,336,429.02 38.152  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 31.03.2026 FTMO.LN IE000CY30YV9 3,050,002.00 USD 80,580,089.95 26.420  ...
-

New Fortress Energy Inc. Announces Results of Early Consent Solicitation and Extension of Early Consent Deadline to April 8, 2026

NEW YORK--(BUSINESS WIRE)--New Fortress Energy Inc. (NASDAQ: NFE) (“NFE” or the “Company”) previously announced on March 17, 2026 that it entered into a Restructuring Support Agreement (“RSA”) with its creditors as part of a consensual UK Restructuring Plan (“UK RP”). NFE is pleased to announce that it has received strong indications of support for the previously announced transaction, to be implemented through a UK RP, from its stakeholders, including holders and lenders representing over 95%...
-

Natixis Syndicate UK Regulatory Announcement: Pre-stabilisation Announcement

LONDON--(BUSINESS WIRE)--  PRE-STABILISATION ANNOUNCEMENT Date: 1st April 2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. KBC Bank NV Pre-stabilisation Period Announcement Natixis (contact: Christopher Agathangelou; telephone: 0158550814) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance...
-

Herbalife to Announce First Quarter 2026 Results on May 6

LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, will release its first quarter 2026 financial results after the close of trading on the NYSE on Wednesday, May 6, 2026. On the same day, at 5:30 p.m. ET (2:30 p.m. PT), Herbalife's senior management team will host an audio webcast and conference call to discuss its recent financial results. The audio webcast will be available at the following link: https://edge.media-server.c...
-

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

WALTHAM, Mass.--(BUSINESS WIRE)--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Korsana Biosciences, Inc. and trade on...